$ABBV Company News FDA approves AbbVie’s hep
Post# of 72704
Posted On: 12/20/2014 12:17:04 PM
$ABBV Company News
FDA approves AbbVie’s hepatitis treatment 3:33 p.m. Dec. 19, 2014 - Peter Loftus
AbbVie's stock gains 0.8% after FDA approval of hepatitis C treatment 3:21 p.m. Dec. 19, 2014 - Tomi Kilgore
Which stocks the billionaires are buying — and selling 1:32 p.m. Dec. 12, 2014 - The Trading Deck
Paulson takes stake in Abbvie, adds to Shire holdings 6:46 p.m. Nov. 14, 2014 - MarketWatch
Obama considering Lazard banker for Treasury post 4:20 p.m. Nov. 12, 2014 - Victoria McGrane
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
S&P 500, Dow close at record levels 4:16 p.m. Oct. 31, 2014 - Barbara Kollmeyer
Apple rallies to record high; LinkedIn jumps 11:05 a.m. Oct. 31, 2014 - Sue Chang
AbbVie stock up 3.6% at $63.38 9:32 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie shares up 4% in premarket trade 8:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie raises outlook as profit, sales beat 8:26 a.m. Oct. 31, 2014 - MarketWatch.com
AbbVie shares up 2% as profit, sales beat estimates 8:00 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie prior FY EPS outlook was $3.06 to $3.16 7:54 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie's stock gains 2.2% premarket after Q3 results beat expectations 7:53 a.m. Oct. 31, 2014 - Tomi Kilgore
AbbVie raises FY EPS outlook to $3.25 to $3.27 7:53 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 FactSet revenue consensus $4.831 bln 7:53 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 FactSet EPS consensus 77 cents 7:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 revenue $5.019 bln, up 7.85 7:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 adj. EPS 89 cents 7:52 a.m. Oct. 31, 2014 - Ciara Linnane
While Gilead's Profits Soar, Uncertainty Reigns Supreme At AbbVie 7:55 p.m. Dec. 19, 2014 - Seeking Alpha
FDA Backs AbbVie’s Hepatitis Treatment 6:21 p.m. Dec. 19, 2014 - The Wall Street Journal Interactive Edition
AbbVie's Hep C Regimen OK'd, 12-Week Cost $83,319 6:05 p.m. Dec. 19, 2014 - Investors Business Daily
Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog 5:20 p.m. Dec. 19, 2014 - Zacks.com
AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog 4:48 p.m. Dec. 19, 2014 - Zacks.com
Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next 4:16 p.m. Dec. 19, 2014 - TheStreet.com
The Dividend Growth Investor's Version Of 'A Christmas Carol' 3:49 p.m. Dec. 19, 2014 - Seeking Alpha
Pharma Favorites to Stand the Trials of 2015 2:29 p.m. Dec. 19, 2014 - Barrons.com
Galapagos earns milestone from AbbVie 8:09 a.m. Dec. 19, 2014 - Seeking Alpha
NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog 6:30 p.m. Dec. 18, 2014 - Zacks.com
Tax Inversions Wrap Up 3:01 p.m. Dec. 18, 2014 - Seeking Alpha
Is it Time to Sell Gilead Sciences? 10:27 a.m. Dec. 18, 2014 - GuruFocus.com
'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield 6:00 a.m. Dec. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity 8:16 p.m. Dec. 17, 2014 - TheStreet.com
AbbVie Pins Hopes on Hepatitis C Treatment 7:52 p.m. Dec. 17, 2014 - The Wall Street Journal Interactive Edition
Novartis Successfully Expands Signifor Label in the U.S. - Analyst Blog 4:45 p.m. Dec. 17, 2014 - Zacks.com
Examining Gilead Sciences' Future Pipeline 7:37 a.m. Dec. 17, 2014 - Seeking Alpha
What's More Powerful Than Compound Interest? 9:58 p.m. Dec. 16, 2014 - Seeking Alpha
Assessing Gilead's Reality-Perception Gap 11:52 a.m. Dec. 16, 2014 - Seeking Alpha
What's More Powerful Than Compound Interest? 10:47 a.m. Dec. 16, 2014 - GuruFocus.com
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting 8:15 p.m. Dec. 7, 2014 - PR Newswire - PRF
Gardy & Notis LLP Issues Notice Of The Filing Of A Securities Class Action Against AbbVie And Its Chief Executive Officer 4:00 p.m. Nov. 26, 2014 - PR Newswire - PRF
CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe 8:00 a.m. Nov. 21, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 7:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 4:48 p.m. Nov. 14, 2014 - PR Newswire - PRF
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 9:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 8:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update 4:01 p.m. Nov. 6, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty 8:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
AbbVie to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
ABBVIE INC. ALERT -- Andrews & Springer LLC is Investigating AbbVie Inc. for Potential Securities Fraud and Breach of Fiduciary Duty 8:09 a.m. Nov. 3, 2014 - GlobeNewswire
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) 7:05 a.m. Nov. 3, 2014 - GlobeNewswire
CMK Select Recognized as Women's Business Enterprise 10:45 a.m. Oct. 31, 2014 - Marketwired
AbbVie Reports Third-Quarter 2014 Financial Results 7:49 a.m. Oct. 31, 2014 - PR Newswire - PRF
If You Purchased Shire plc American Depository Receipts ("ADRs"
During The Period Of June 20, 2014 And October 14, 2014 And Lost Money, Gardy & Notis, LLP Encourages You To Contact The Law Firm 8:38 a.m. Oct. 29, 2014 - PR Newswire - PRF
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly 8:35 a.m. Oct. 29, 2014 - PR Newswire - PRF
AbbVie Named a Top Employer in Science Magazine's Annual Survey for Second Consecutive Year 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
Merger Deal Updates, Dividend, Dispute Settlement, Regulatory Application Submission, and Preliminary Results - Research Reports on Shire, Johnson & Johnson, Merck, Amgen and HCA 9:00 a.m. Oct. 21, 2014 - PR Newswire - PRF
FDA approves AbbVie’s hepatitis treatment 3:33 p.m. Dec. 19, 2014 - Peter Loftus
AbbVie's stock gains 0.8% after FDA approval of hepatitis C treatment 3:21 p.m. Dec. 19, 2014 - Tomi Kilgore
Which stocks the billionaires are buying — and selling 1:32 p.m. Dec. 12, 2014 - The Trading Deck
Paulson takes stake in Abbvie, adds to Shire holdings 6:46 p.m. Nov. 14, 2014 - MarketWatch
Obama considering Lazard banker for Treasury post 4:20 p.m. Nov. 12, 2014 - Victoria McGrane
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
S&P 500, Dow close at record levels 4:16 p.m. Oct. 31, 2014 - Barbara Kollmeyer
Apple rallies to record high; LinkedIn jumps 11:05 a.m. Oct. 31, 2014 - Sue Chang
AbbVie stock up 3.6% at $63.38 9:32 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie shares up 4% in premarket trade 8:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie raises outlook as profit, sales beat 8:26 a.m. Oct. 31, 2014 - MarketWatch.com
AbbVie shares up 2% as profit, sales beat estimates 8:00 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie prior FY EPS outlook was $3.06 to $3.16 7:54 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie's stock gains 2.2% premarket after Q3 results beat expectations 7:53 a.m. Oct. 31, 2014 - Tomi Kilgore
AbbVie raises FY EPS outlook to $3.25 to $3.27 7:53 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 FactSet revenue consensus $4.831 bln 7:53 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 FactSet EPS consensus 77 cents 7:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 revenue $5.019 bln, up 7.85 7:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie Q3 adj. EPS 89 cents 7:52 a.m. Oct. 31, 2014 - Ciara Linnane
While Gilead's Profits Soar, Uncertainty Reigns Supreme At AbbVie 7:55 p.m. Dec. 19, 2014 - Seeking Alpha
FDA Backs AbbVie’s Hepatitis Treatment 6:21 p.m. Dec. 19, 2014 - The Wall Street Journal Interactive Edition
AbbVie's Hep C Regimen OK'd, 12-Week Cost $83,319 6:05 p.m. Dec. 19, 2014 - Investors Business Daily
Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog 5:20 p.m. Dec. 19, 2014 - Zacks.com
AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog 4:48 p.m. Dec. 19, 2014 - Zacks.com
Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next 4:16 p.m. Dec. 19, 2014 - TheStreet.com
The Dividend Growth Investor's Version Of 'A Christmas Carol' 3:49 p.m. Dec. 19, 2014 - Seeking Alpha
Pharma Favorites to Stand the Trials of 2015 2:29 p.m. Dec. 19, 2014 - Barrons.com
Galapagos earns milestone from AbbVie 8:09 a.m. Dec. 19, 2014 - Seeking Alpha
NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog 6:30 p.m. Dec. 18, 2014 - Zacks.com
Tax Inversions Wrap Up 3:01 p.m. Dec. 18, 2014 - Seeking Alpha
Is it Time to Sell Gilead Sciences? 10:27 a.m. Dec. 18, 2014 - GuruFocus.com
'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield 6:00 a.m. Dec. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity 8:16 p.m. Dec. 17, 2014 - TheStreet.com
AbbVie Pins Hopes on Hepatitis C Treatment 7:52 p.m. Dec. 17, 2014 - The Wall Street Journal Interactive Edition
Novartis Successfully Expands Signifor Label in the U.S. - Analyst Blog 4:45 p.m. Dec. 17, 2014 - Zacks.com
Examining Gilead Sciences' Future Pipeline 7:37 a.m. Dec. 17, 2014 - Seeking Alpha
What's More Powerful Than Compound Interest? 9:58 p.m. Dec. 16, 2014 - Seeking Alpha
Assessing Gilead's Reality-Perception Gap 11:52 a.m. Dec. 16, 2014 - Seeking Alpha
What's More Powerful Than Compound Interest? 10:47 a.m. Dec. 16, 2014 - GuruFocus.com
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting 8:15 p.m. Dec. 7, 2014 - PR Newswire - PRF
Gardy & Notis LLP Issues Notice Of The Filing Of A Securities Class Action Against AbbVie And Its Chief Executive Officer 4:00 p.m. Nov. 26, 2014 - PR Newswire - PRF
CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe 8:00 a.m. Nov. 21, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 7:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 4:48 p.m. Nov. 14, 2014 - PR Newswire - PRF
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 9:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 8:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update 4:01 p.m. Nov. 6, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty 8:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
AbbVie to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
ABBVIE INC. ALERT -- Andrews & Springer LLC is Investigating AbbVie Inc. for Potential Securities Fraud and Breach of Fiduciary Duty 8:09 a.m. Nov. 3, 2014 - GlobeNewswire
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) 7:05 a.m. Nov. 3, 2014 - GlobeNewswire
CMK Select Recognized as Women's Business Enterprise 10:45 a.m. Oct. 31, 2014 - Marketwired
AbbVie Reports Third-Quarter 2014 Financial Results 7:49 a.m. Oct. 31, 2014 - PR Newswire - PRF
If You Purchased Shire plc American Depository Receipts ("ADRs"
During The Period Of June 20, 2014 And October 14, 2014 And Lost Money, Gardy & Notis, LLP Encourages You To Contact The Law Firm 8:38 a.m. Oct. 29, 2014 - PR Newswire - PRF Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly 8:35 a.m. Oct. 29, 2014 - PR Newswire - PRF
AbbVie Named a Top Employer in Science Magazine's Annual Survey for Second Consecutive Year 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
Merger Deal Updates, Dividend, Dispute Settlement, Regulatory Application Submission, and Preliminary Results - Research Reports on Shire, Johnson & Johnson, Merck, Amgen and HCA 9:00 a.m. Oct. 21, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼